18 September 2017 - First and only single dose oral therapy approved for most common U.S. gynecologic infection that can have serious health risks if inadequately treated.

Symbiomix Therapeutics today announced the U.S. FDA has approved Solosec (secnidazole) 2 g oral granules for the treatment of bacterial vaginosis in adult women. 

Solosec is a potent, next-generation, 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties that enable delivery in a single dose that’s been shown to be efficacious and well tolerated.

Read Symbiomix Therapeutics press release